{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:18:00Z","timestamp":1783052280679,"version":"3.54.6"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2025-00554335"],"award-info":[{"award-number":["RS-2025-00554335"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116691","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:23:52Z","timestamp":1777292632000},"page":"116691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mycobacterial fusion protein REA eliciting anti-tumor activity through activation of innate immunity"],"prefix":"10.1016","volume":"181","author":[{"given":"Thuy An","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunga","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sintayehu Kebede","family":"Gurmessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Gyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeo-Jin","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Woo","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Taek","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-bok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Hee","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZongYou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.116691_bb0010","series-title":"Current challenges and future advances in lung cancer: Genetics, instrumental diagnosis and treatment","first-page":"3710","author":"Vicidomini","year":"2023"},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"Majeed","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0025","article-title":"Emerging cancer immunotherapies: cutting-edge advances and innovations in development","volume":"12","author":"Maccagno","year":"2024","journal-title":"Med. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.32604\/or.2025.057842","article-title":"Mycobacterial antigen Ag85B restrains hodgkin lymphoma tumor growth by inhibiting autophagy","volume":"33","author":"Cheng","year":"2025","journal-title":"Oncol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0035","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116691_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory t cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.intimp.2026.116691_bb0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ t cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116691_bb0065","doi-asserted-by":"crossref","first-page":"1372995","DOI":"10.3389\/fsysb.2024.1372995","article-title":"Crosstalking with dendritic cells: a path to engineer advanced t cell immunotherapy","volume":"4","author":"Schafer","year":"2024","journal-title":"Front. Syst. Biol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0070","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/cancers14051179","article-title":"Epigenetics of dendritic cells in tumor immunology","volume":"14","author":"Godoy-Tena","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116691_bb0075","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116691_bb0080","series-title":"Seminars in Immunology","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","author":"Marciscano","year":"2021"},{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/JLB.3MIR0320-475R","article-title":"The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance","volume":"108","author":"Chang","year":"2020","journal-title":"Journal of Leucocyte Biology"},{"issue":"2","key":"10.1016\/j.intimp.2026.116691_bb0095","doi-asserted-by":"crossref","first-page":"2350778","DOI":"10.1002\/eji.202350778","article-title":"Current advances in bacteria-based cancer immunotherapy","volume":"54","author":"Guo","year":"2024","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116691_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202003572","article-title":"Bacteria-based cancer immunotherapy","volume":"8","author":"Huang","year":"2021","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2025.01.029","article-title":"Transforming bacterial pathogens into wonder tools in cancer immunotherapy","volume":"33","author":"Senevirathne","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.116691_bb0110","article-title":"Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116691_bb0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15430\/JCP.23.036","article-title":"Efficacy of bacillus Calmette-Gu\u00e9rin in cancer prevention and its putative mechanisms","volume":"29","author":"Gupta","year":"2024","journal-title":"J. Cancer Prevent."},{"issue":"7","key":"10.1016\/j.intimp.2026.116691_bb0130","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3390\/cancers12071802","article-title":"Mycobacteria-based vaccines as immunotherapy for non-urological cancers","volume":"12","author":"Noguera-Ortega","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116691_bb0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.omto.2021.10.003","article-title":"Mycobacterium tuberculosis rv3628 is an effective adjuvant via activation of dendritic cells for cancer immunotherapy","volume":"23","author":"Wu","year":"2021","journal-title":"Molecular Therapy-Oncolytics"},{"issue":"25","key":"10.1016\/j.intimp.2026.116691_bb0140","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.7150\/jca.29779","article-title":"MTBHsp70-exFPR1-pulsed dendritic cells enhance the immune response against cervical cancer","volume":"10","author":"Cao","year":"2019","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-025-01077-1","article-title":"Novel fusion protein REA induces robust prime protection against tuberculosis in mice","volume":"10","author":"Gurmessa","year":"2025","journal-title":"npj Vaccines"},{"issue":"11","key":"10.1016\/j.intimp.2026.116691_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9110865","article-title":"Fusion of dendritic cells activating rv2299c protein enhances the protective immunity of Ag85B-ESAT6 vaccine candidate against tuberculosis","volume":"9","author":"Back","year":"2020","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.intimp.2026.116691_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020300","article-title":"Antigen-specific IFN-\u03b3\/IL-17-co-producing CD4+ t-cells are the determinants for protective efficacy of tuberculosis subunit vaccine","volume":"8","author":"Choi","year":"2020","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213536","article-title":"Cell wall skeleton of mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing th1 and th17 responses","volume":"14","author":"Back","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.116691_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2014.10.007","article-title":"Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model","volume":"196","author":"Nakamura","year":"2014","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.intimp.2026.116691_bb0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/BF02976612","article-title":"Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice","volume":"25","author":"Yoo","year":"2002","journal-title":"Arch. Pharm. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050516","article-title":"BCG cell wall skeleton as a vaccine adjuvant protects both infant and old-aged mice from influenza virus infection","volume":"9","author":"Kim","year":"2021","journal-title":"Biomedicines"},{"issue":"50","key":"10.1016\/j.intimp.2026.116691_bb0180","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1016\/j.vaccine.2010.09.083","article-title":"Mycobacterial cell-wall skeleton as a universal vaccine vehicle for antigen conjugation","volume":"28","author":"Paik","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2026.116691_bb0185","article-title":"Alum adjuvant and built-in TLR7 agonist synergistically enhance anti-MUC1 immune responses for cancer vaccine","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"issue":"52","key":"10.1016\/j.intimp.2026.116691_bb0190","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032481","article-title":"A retrospective study of immunotherapy using the cell wall skeleton of mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG-CWS) for cervical cancer","volume":"101","author":"Shibata","year":"2022","journal-title":"Medicine"},{"issue":"12","key":"10.1016\/j.intimp.2026.116691_bb0195","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2026.116691_bb0200","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1111\/cas.14116","article-title":"Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity","volume":"110","author":"Inao","year":"2019","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.116691_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274056","article-title":"Comprehensive analysis of different tumor cell-line produced soluble mediators on the differentiation and functional properties of monocyte-derived dendritic cells","volume":"17","author":"Burai","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2015.10.009","article-title":"Immunotherapy and tumor microenvironment","volume":"370","author":"Tang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116691_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859177","article-title":"Innovative strategies to improve the clinical application of NK cell-based immunotherapy","volume":"13","author":"Tarannum","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116691_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2013a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0225","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in t cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116691_bb0230","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0235","article-title":"The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.intimp.2026.116691_bb0240","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.4049\/jimmunol.1400656","article-title":"Enhancement of tumor-specific T cell\u2013mediated immunity in dendritic cell\u2013based vaccines by Mycobacterium tuberculosis heat shock protein X","volume":"193","author":"Jung","year":"2014","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0245","doi-asserted-by":"crossref","first-page":"6090","DOI":"10.1038\/s41467-023-41768-8","article-title":"Intravenous administration of BCG in mice promotes natural killer and t cell-mediated antitumor immunity in the lung","volume":"14","author":"Moreo","year":"2023","journal-title":"Nat. Commun."},{"issue":"32","key":"10.1016\/j.intimp.2026.116691_bb0250","doi-asserted-by":"crossref","first-page":"33781","DOI":"10.18632\/oncotarget.5281","article-title":"Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity","volume":"6","author":"Vo","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2026.116691_bb0255","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2023340","article-title":"Potential of mycobacterium tuberculosis chorismate mutase (rv1885c) as a novel TLR4-mediated adjuvant for dendritic cell-based cancer immunotherapy","volume":"11","author":"Jeong","year":"2022","journal-title":"Oncoimmunology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926005370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:36:41Z","timestamp":1783049801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926005370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"alternative-id":["S1567576926005370"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116691","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycobacterial fusion protein REA eliciting anti-tumor activity through activation of innate immunity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116691"}}